List view / Grid view

non-small cell lung cancer

Filter the results

 

news

AstraZeneca’s lung cancer drug receives full approval in the EU

27 April 2017 | By Niamh Marriott, Junior Editor

The European Commission (EC) has granted full marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

news

AstraZeneca lung cancer drug receives FDA approval

4 April 2017 | By Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted full approval for AstraZeneca’s Tagrisso (osimertinib) tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR…

news

Expanded Phase II trial of savolitinib in NSCLC starts

20 June 2016 | By Victoria White, Digital Content Producer

A Phase II expansion of the ongoing TATTON trial has been initiated to evaluate savolitinib (AZD6094) in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients.

news

Incyte and AstraZeneca announce new lung cancer trial collaboration

11 January 2016 | By Victoria White

Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…